Candesartan is just as effective as more the commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and ...
Tags: High-Blood Pressure, Prevent Migraines, High-Blood Pressure Medicine
The U.S. Food and Drug Administration (FDA) is now accepting online submission of voluntary and mandatory dietary supplement adverse event reports. The FDA has implemented a secure capability in the interest of efficiency and as a ...
Tags: FDA, Dietary Supplement Adverse, secure capability, physician
HealthCare.gov famously failed at launch, not delivering what was promised. Depending on whom you ask - and whom you believe - the cost to taxpayers ranges from $654 million to well over $1 billion. If, as Professor Van Helsing said in Bram ...
Tags: Fleet Software, Transportation
Hello Products LLC, the world's first line of seriously friendly oral care products, is pleased to announce it is the recipient of a 2013 Good Design Award for Design Excellence. Chosen from thousands of entries submitted from more than 38 ...
Tags: Hello Products, 2013 Good Design Award, Design Excellence
According to newly published results from a survey of pharmacy directors, drug shortages remain a serious problem for patient safety. Nearly half of the responding directors reported adverse events at their facilities due to drug shortages, ...
Tags: drug shortages, patient care, adverse effects, patient outcomes
Most clinical studies of vitamins are "flawed by poor methodology", review finds Most large clinical trials of vitamin supplements, including those that have concluded supplements are of no value or even harmful, have a “flawed ...
Tags: vitamin supplements, flawed methodology, useless, micronutrients
A new, preliminary treatment involving triple-gene therapy appears safe and effective in helping to control motor function in Parkinson's disease patients, according to new research. The therapy, called ProSavin, works by reprogramming ...
Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients ...
Tags: Altheus Therapeutics, enrollment, ZA201, Zoenasa®Rectal Gel
Findings of a preliminary study published in The Lancet Respiratory Medicine suggest that a patient's own bone-marrow stromal (stem) cells could be used to treat multidrug-resistant (MDR) and extensively-drug (XDR) tuberculosis (TB). ...
Tags: bone-marrow stromal cells, multidrug-resistant tuberculosis
Harvard stem cells scientists at Brigham and Women's Hospital and MIT can now engineer cells that are more easily controlled following transplantation, potentially making cell therapies, hundreds of which are currently in clinical trials ...
Tags: stem cells
Concussions can't be prevented, treated or cured with dietary supplements, according to the U.S. Food and Drug Administration. The agency issued a warning against these products in response to a number of false claims, including promises ...
K2M, Inc., the largest privately held spinal device company in the world focused on developing innovative solutions for the treatment of complex spinal pathologies and minimally invasive procedures, today announced it has received 510(k) ...
Tags: K2M, CAYMAN Minimally Invasive, CAYMAN Plate System, 510(k)clearance
More than a week after marijuana prohibition came to an end in Colorado, the joy has faded as residents adjust to the new normal of having the most liberal marijuana laws in the U.S. Long lines are gone from the 37 -- and counting -- pot ...
The U.S. Food and Drug Administration on Friday approved Mekinist for use with another drug, Tafinlar, to treat advanced melanoma that is spreading or cannot be removed by surgery. Melanoma is the most deadly form of skin cancer, ...
As fewer Americans smoke, the number of people who develop lung cancer continues to drop, U.S. health officials report. Between 2005 and 2009, lung cancer rates went down 2.6 percent each year among men, from 87 to 78 cases per 100,000, ...